Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
MolecularMatch announced the USPTO has issued a patent covering its Precision Medicine Service for use by hospitals, pharmaceutical companies, laboratories, and health information systems.
read more
Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX), is set to increase awareness and uptake of its pharmaceutical development services in the North American market following the appointment of a new head of US sales.
read more
Tuesday, October 13, 2020
Mogrify announced the introduction of EpiMOGRIFY. The platform models the epigenetic state of the cell to predict the switches important for cell identity, cell maintenance, directed differentiation and cell conversion.
read more
Thursday, January 14, 2021
Mogrify and the MRC Laboratory of Molecular Biology (LMB) have announced an exploratory research collaboration.
read more
Thursday, December 22, 2016
Moffitt Cancer Center has chosen Cryoport, Inc. to provide support for its immunology program, cancer research, and therapy programs and lab moves.
read more
Moffitt Cancer Center announced today the launch of a first-of-its-kind contract research organization (CRO) focused on accelerating immunotherapy research. The subsidiary will provide a one-stop-shop for pharmaceutical and biotech companies to ...
read more
Moderna and Lonza announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna’s mRNA vaccine against the novel coronavirus.
read more
Moderna and Catalent announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate at Catalent’s biologics facility in Indiana.
read more
Wednesday, November 01, 2017
Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and co-commercialize an mRNA therapeutic encoding for Relaxin.
read more
Moderna has announced the Company has shipped the 100-millionth dose of its COVID-19 vaccine to the U.S. Government.
read more
Moderna Therapeutics announced the opening of its state-of-the-art manufacturing facility in Norwood, Massachusetts.
read more
Thursday, August 03, 2017
Moderna announced Juan Andres has joined the company as Senior Vice President of Late Stage Technical Development and Manufacturing (beyond human proof of concept).
read more
Monday, November 16, 2020
Moderna announced the DSMB for the Phase 3 study of mRNA-1273 has informed the company the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.
read more
Moderna has announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against COVID-19 has begun dosing participants.
read more
Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that it has entered into an additional agreement with Lonza to support drug substance manufacturing for its global supply chain. The agreement will ...
read more